tm logo
CBIS
Dead/Abandoned
ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE

failure to respond or late response

on 25 Aug 2020

Last Applicant/ Owned by

19800 MacArthur Blvd., Suite #300

Irvine

CA

92612

Serial Number

88045390 filed on 19th Jul 2018

Registration Number

N/A

Correspondent Address

Faiyaz Dean

Faiyaz Dean

701 5TH AVENUE, SUITE 4200

SEATTLE, WA 98104

Filing Basis

1. use application currently

Disclaimer

NO DATA

CBIS

Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in ti Read More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Drug delivery agents that provide controlled release of the active ingredients for a wide variety of cannabinoid pharmaceuticals; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Therapeutic pharmaceutical for the treatment and prevention of inflammatory bowel disease; Pharmaceutical preparations for use in gastroenterology; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Therapeutic pharmaceutical for the treatment and prevention of neurodegenerative disease; Therapeutic pharmaceutical for the treatment and prevention of neurological disorders; Pharmaceutical preparations for use in neurology; Pharmaceutical preparations and substances for the treatment and prevention of psychiatric diseases and disorders; Therapeutic pharmaceutical for the treatment and prevention of autoimmune conditions; Therapeutic pharmaceutical for the treatment and prevention of inflammation; Pharmaceutical preparations for the treatment and prevention of immune system related diseases and disorders; Therapeutic pharmaceutical for the treatment and prevention of pain; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Therapeutic pharmaceutical for the treatment of infections; Therapeutic pharmaceutical for the treatment of drug-resistant infections; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical agents affecting sensory organs; Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical preparations for use in urology; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in opthalmology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical products for treating respiratory diseases; Pharmaceutical preparations for skin care; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Ocular pharmaceuticals; Antibacterial pharmaceuticals; Pharmaceuticals, namely, anti-infectives


First Use Date in General

07th May 2009

First Use Date in Commerce

07th May 2009

Mark Details


Serial Number

No 88045390

Mark Type

No Service/Collective Mark

Attorney Docket Number

No

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Design Code(s)

01.09.05 -

Atoms or molecular models

01.09.25 -

Other planets, asteroids, meteors

Legal History


Show more

Status DateAction Taken
25th Aug 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
25th Aug 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
12th Feb 2020NON-FINAL ACTION E-MAILED
12th Feb 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
12th Feb 2020NON-FINAL ACTION WRITTEN
14th Jan 2020TEAS/EMAIL CORRESPONDENCE ENTERED
14th Jan 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
14th Jan 2020ASSIGNED TO LIE
24th Dec 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
25th Jun 2019NON-FINAL ACTION E-MAILED